A Double-Blind Study of Tranylcypromine Treatment of Major Anergic Depression
The DOI matches its Crossref record.
Abstract
Fifty-nine anergically depressed patients were randomly assigned to 6 weeks of double-blind treatment with either tranylcypromine or placebo. Anergic major depression most typically occurs in primary bipolar and in pseudounipolar affective illnesses. We hypothesized that tranylcypromine would be a highly effective and rapid treatment for depressions of this type. Results of repeated measures analyses of variance showed superiority of active drug over placebo by the end of the first week, and this improvement increased in significance at each successive visit. Improvement on tranylcypromine after week 1 was greater than that on placebo after week 6. Analysis of covariance of week 6 scores (corrected for week 0 scores) showed significantly greater improvement for tranylcypromine patients on all measures of depressive symptomatology. Tranylcypromine is a rapid, relatively safe, and dramatically effective treatment for anergic depression. Since 24 of 29 of the bipolar subjects had previously failed to respond to tricyclics and since bipolar depression is usually anergic, tranylcypromine should be compared to imipramine to determine the antidepressant of choice for manic-depressive illness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other classes of antidepressants such as serotonin‐ norepinephrine reuptake inhibitors [SNRIs] and monoamine oxidase inhibitors [MAOIs] could be used adjunctively but clinicians need to ensure adequate anti‐manic prophylaxis in such situations, as SNRIs and MAOIs have a higher propensity than other antidepressants to induce manic switch and cause mood destabilization (level 2).276, 277, 278”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“In a RCT of BDI and BDII pa ents, bupropion was shown to be as effec ve as sertraline and venlafaxine (277).”
MethodPRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Gijsman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1537 · Cited by 563
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“Several small controlled studies support the use of deprenyl (Mendlewicz and Youdim 1980), tranylcypromine (Himmelhoch et al. 1982; Nolen et al. 2007), imipramine and fl uoxetine (Cohn et al.”
Result
Metadata
- Authors
- HIMMELHOCH, J. M., FUCHS, C. Z., & SYMONS, B. J.
- Affiliations
- University of Pittsburgh (US)
- Venue
- The Journal of Nervous and Mental Disease
- Published
- 1982-10
- Volume
- 170
- Issue
- 10
- Pages
- 628-634
- ISSN
- 0022-3018 (ISSN-L)
- OpenAlex
- W1980181121
- Cited by
- 103
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 4 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 5 · 2013: 1 · 2012: 2
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Nervous and Mental Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- tranylcypromine, major depressive disorder, bipolar disorder, antidepressant efficacy, placebo comparison, rapid antidepressant response, imipramine, depressive symptoms
- MeSH terms
- Adult, Ambulatory Care, Bipolar Disorder, Clinical Trials as Topic, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Placebos, Psychiatric Status Rating Scales, Tranylcypromine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind Study of Tranylcypromine Treatment of Major Anergic Depression. https://app.cochat.ai/papers/10.1097/00005053-198210000-00007
- The paper
- HIMMELHOCH, J. M., FUCHS, C. Z., & SYMONS, B. J. (1982). A Double-Blind Study of Tranylcypromine Treatment of Major Anergic Depression. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-198210000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.